+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Doxorubicin - Global Strategic Business Report

  • PDF Icon

    Report

  • 288 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5302837
The global market for Doxorubicin is estimated at US$1.1 Billion in 2023 and is projected to reach US$1.7 Billion by 2030, growing at a CAGR of 5.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the doxorubicin market is driven by several factors. The increasing incidence of cancer globally is a significant driver, as more patients require effective chemotherapeutic options. Advances in drug delivery technologies, such as liposomal formulations and nanoparticles, are enhancing the efficacy and safety profile of doxorubicin, encouraging its wider adoption. Furthermore, the expanding field of precision medicine is supporting the development of more tailored treatment regimens, potentially increasing the use of doxorubicin in combination therapies. Pharmaceutical companies are also investing heavily in research and development to explore new indications and combination treatments involving doxorubicin. Additionally, improvements in healthcare infrastructure and increased access to cancer treatment in emerging markets are boosting the demand for effective chemotherapy agents. These factors collectively underscore the dynamic and evolving nature of the doxorubicin market, driven by technological advancements, rising cancer prevalence, and ongoing research efforts.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Breast Cancer Application segment, which is expected to reach US$374.1 Million by 2030 with a CAGR of a 5.6%. The Lung Cancer Application segment is also set to grow at 7.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $468.8 Million in 2023, and China, forecasted to grow at an impressive 8.1% CAGR to reach $145.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Doxorubicin Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Doxorubicin Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Doxorubicin Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Merck KGaA, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 59 Featured):

  • Merck KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • Natco Pharma Limited
  • Meiji Holdings Co., Ltd.
  • Celsion Corporation
  • Health Biotech Ltd.
  • MicroBiopharm Japan Co., Ltd.
  • Accord Healthcare Ltd.
  • Olon S.p.A.
  • Seqens SAS
  • Biovencer Healthcare Private Limited
  • Avacta Group
  • CSPC Pharmaceutical Group Limited

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Doxorubicin - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Cancer - An Insight
  • Cancer Treatment
  • Chemotherapy: An Overview
  • An Introduction to Doxorubicin
  • GLOBAL MARKET OVERVIEW
  • Global Doxorubicin Market Set to Witness Rapid Growth
  • US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
  • Breast Cancer Constitutes the Largest Application for Doxorubicin
  • Competition
  • New Entrants Seek Opportunities
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rise in Cancer Incidence to Drive Market Growth
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Liposomal Delivery Systems Offer Significant Benefits
  • A Review of Liposomal-Doxorubicin Preparations
  • DOX Hydrochloride
  • Ageing Demographics to Drive Demand
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • Market to Gain from Rise in Number of Breast Cancer Cases
  • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
  • Age-Standardized Lung Cancer Rates for Select Countries
  • Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
  • Uptrend in Healthcare Spending Drives the Doxorubicin Demand
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
  • Cancer Research Spending Continues to Witness Growth
  • A Netherlands Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect
  • Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
  • Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
  • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
  • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
  • Combination Therapy: A Double Whammy Success
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 23: World Historic Review for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 24: World 16-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 28: World Doxorubicin Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • MARKET ANALYSIS
  • Rising Cancer Cases Spur Growth in Doxorubicin Market
  • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
  • Table 29: USA Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 30: USA Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: USA 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
CANADA
  • Table 32: Canada Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: Canada 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
JAPAN
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: Japan 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
CHINA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: China Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: China 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
EUROPE
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • MARKET ANALYSIS
  • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
  • Table 41: Europe Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 42: Europe Historic Review for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: Europe 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 44: Europe Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: Europe 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
FRANCE
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 47: France Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 48: France Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: France 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
GERMANY
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 50: Germany Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Germany Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: Germany 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
ITALY
  • Table 53: Italy Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: Italy Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: Italy 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 56: UK Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: UK Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: UK 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
SPAIN
  • Table 59: Spain Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: Spain Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: Spain 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
RUSSIA
  • Table 62: Russia Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Russia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: Russia 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 65: Rest of Europe Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: Rest of Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: Rest of Europe 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • MARKET ANALYSIS
  • An Insight into Asia-Pacific Market for Doxorubicin
  • Table 68: Asia-Pacific Recent Past, Current & Future Analysis for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 69: Asia-Pacific Historic Review for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: Asia-Pacific 16-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 71: Asia-Pacific Recent Past, Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: Asia-Pacific Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: Asia-Pacific 16-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2014, 2024 & 2030
AUSTRALIA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Doxorubicin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • Natco Pharma Limited
  • Meiji Holdings Co., Ltd.
  • Celsion Corporation
  • Health Biotech Ltd.
  • MicroBiopharm Japan Co., Ltd.
  • Accord Healthcare Ltd.
  • Olon S.p.A.
  • Seqens SAS
  • Biovencer Healthcare Private Limited
  • Avacta Group
  • CSPC Pharmaceutical Group Limited

Table Information